Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Colorcon
US Army
Johnson and Johnson
Express Scripts
Medtronic
Queensland Health
Daiichi Sankyo

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,205,052

« Back to Dashboard

Which drugs does patent 9,205,052 protect, and when does it expire?

Patent 9,205,052 protects EXPAREL and is included in one NDA.

This patent has twenty patent family members in fifteen countries.
Summary for Patent: 9,205,052
Title:Sustained-release liposomal anesthetic compositions
Abstract: The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.
Inventor(s): Kim; Sinil (La Jolla, CA), Kim; Taehee (Carlsbad, CA), Murdande; Sharad (Waterford, CT)
Assignee: Pacira Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/842,198
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,205,052

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-002 Oct 28, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,205,052

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,192,575 Sustained-release liposomal anesthetic compositions ➤ Try a Free Trial
6,045,824 Sustained-release liposomal anesthetic compositions ➤ Try a Free Trial
8,834,921 Sustained-release liposomal anesthetic compositions ➤ Try a Free Trial
8,182,835 Sustained-release liposomal anesthetic compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,205,052

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong 1145966 ➤ Try a Free Trial
Canada 2304096 ➤ Try a Free Trial
Cyprus 1110135 ➤ Try a Free Trial
Germany 69841598 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Healthtrust
Merck
Cantor Fitzgerald
Fish and Richardson
Chinese Patent Office
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.